Cardiff Oncology Inc (NASDAQ:CRDF) shares, rose in value on Wednesday, June 18, with the stock price down by -18.38% to the previous day’s close as strong demand from buyers drove the stock to $3.02.
Actively observing the price movement in the last trading, the stock closed the session at $3.70. Referring to stock’s 52-week performance, its high was $5.64, and the low was $2.01. On the whole, CRDF has fluctuated by 3.78% over the past month.
With the market capitalization of Cardiff Oncology Inc currently standing at about $200.91 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRDF’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of CRDF currently trading nearly -13.76% and -1.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.82, while the 7-day volatility ratio is showing 10.06% which for the 30-day chart, stands at 6.68%. Furthermore, Cardiff Oncology Inc (CRDF)’s beta value is 1.56, and its average true range (ATR) is 0.29.
A comparison of Cardiff Oncology Inc (CRDF) with its peers suggests the former has fared considerably weaker in the market. CRDF showed an intraday change of -18.38% in last session, and over the past year, it grew by 11.85%%.
Data on historical trading for Cardiff Oncology Inc (NASDAQ:CRDF) indicates that the trading volumes over the past 3 months, they’ve averaged 1.16 million. According to company’s latest data on outstanding shares, there are 66.53 million shares outstanding.
Nearly 8.68% of Cardiff Oncology Inc’s shares belong to company insiders and institutional investors own 42.24% of the company’s shares. The stock has fallen by -30.41% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDF stock heading into the next quarter.
